Recent studies have suggested that RANK (receptor activator of nuclear factor kappa-B) and RANK ligand (RANKL) are associated with breast cancer risk in BRCA gene variant carriers and may be used for precision prevention for treatment [16,17]. This evidence concerns the gene TNFSF11 and breast carcinoma.